Comments to the Food & Drug Administration – Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry | The National Cannabis...

Comments to the Food & Drug Administration – Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry | The National Cannabis Industry Association

Prepared by NCIA

In September 2020, NCIA’s Policy Council, Hemp Committee, and Scientific Advisory Committee collaborated to submit comments to the Food & Drug Administration in response to a call for guidance on research considerations.

NCIA is leading the cannabis industry’s unified and coordinated campaign to ensure our business sector is treated fairly and has the opportunity to reach its full potential. Now – more than ever – is the time to invest in your business and the future of the industry by becoming a member.

This site uses cookies. By using this site or closing this notice, you agree to the use of cookies and our privacy policy.

MJ Shareholders avatar

MJ Shareholders

MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers

No comments so far.

Be first to leave comment below.

( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )